MindBio Therapeutics Begins Pre-Screening Participants for World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder

MindBio Therapeutics Corp. has started the pre-screening process to select participants for its Phase 2 clinical trial on LSD-Microdosing as a treatment for Major Depressive Disorder, making it the first time that take-home approvals have been given for LSD-Microdosing in a clinical trial. &nbsp The initial Phase 2a open-label trial will last for 8 weeks and aims to evaluate the effectiveness of..